Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Bupropion for Binge Eating Disorder in Obesity
NCT02317744Completed
- Sponsor
- Yale University
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of naltrexone and bupropion in binge eating disorder (BED), sponsored by Yale University. Primary endpoint: Binge Eating Frequency at 3 months. Started Dec 2014; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT02317744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317744.